School of Medicine
Showing 1-4 of 4 Results
-
Lawrence Leung
Maureen Lyles D'Ambrogio Professor in the School of Medicine and Senior Associate Dean, Veteran Affairs
Current Research and Scholarly Interests Our long term interest is to have a better understanding of the natural antithrombotic pathways and the pathophysiology of vascular thrombosis. We have focused on thrombin, the key enzyme in the blood clotting cascade.Our goal is to develop new antithrombotic agents and devise new diagnostic tests for vascular thrombotic disorders.
-
Lee Levitt
Professor of Medicine (Hematology) at the Santa Clara Valley Medical Center, Emeritus
Current Research and Scholarly Interests Low molecular-weight heparins Clinical trials with anti-thrombotics Clinical trials in patients with leukemia, breast cancer and myeloma Medical education.
-
Michaela Liedtke
Associate Professor of Medicine (Hematology) at the Stanford University Medical Center
Current Research and Scholarly Interests 1) Design of phase I/II trials for the treatment of Multiple Myeloma and Amyloidosis
2) Conduct of clinical trials to improve the treatment of patients with acute lymphoblastic leukemia (ALL)
3) Outcomes research using clinical databases for patients with Multiple Myeloma and Amyloidosis
4) Characterization of the molecular mechanism of MLL-induced acute leukemia -
Yuan-Hung Lo
Postdoctoral Research Fellow, Hematology
Bio I am currently working on several projects to understand the control of intestinal and colorectal cancer stem cell biology. Stem cells of the intestinal tract give rise to the surface lining of the small and large intestines, and must continuously produce new cells to replace those shed into the lumen throughout the lifespan. When mutations accumulate in these intestinal stem cells, they can grow uncontrollably into benign polyps or colorectal cancers. I have focused my efforts on understanding the molecular mechanisms that regulate stem cell activity in the intestine, and applying this knowledge to gain insight into how these same pathways can control the activity of cancer stem cells.